XML 30 R15.htm IDEA: XBRL DOCUMENT v3.4.0.3
Equity
3 Months Ended
Mar. 31, 2016
Equity [Abstract]  
Equity
9. Equity
Preferred Stock
Preferred stock authorized, issued and outstanding was as follows at both March 31, 2016 and December 31, 2015:
Series
 
Shares
Authorized
 
Shares
Issued
 
Shares
Outstanding
Floating Rate Non-Cumulative Preferred Stock, Series A
 
27,600,000

 
24,000,000

 
24,000,000

5.25% Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series C
 
1,500,000

 
1,500,000

 
1,500,000

Series A Junior Participating Preferred Stock
 
10,000,000

 

 

Not designated
 
160,900,000

 

 

Total
 
200,000,000

 
25,500,000

 
25,500,000

Common Stock
During the three months ended March 31, 2016 and 2015, MetLife, Inc. repurchased 1,445,864 and 19,893,284 shares through open market purchases for $70 million and $986 million, respectively.
At March 31, 2016, MetLife, Inc. had no remaining common stock repurchase authorizations. Common stock repurchases are dependent upon several factors, including the Company’s capital position, liquidity, financial strength and credit ratings, general market conditions, the market price of MetLife, Inc.’s common stock compared to management’s assessment of the stock’s underlying value and applicable regulatory approvals, as well as other legal and accounting factors.
Stock-Based Compensation Plans
Performance Shares and Performance Units
Awards under the MetLife, Inc. 2005 Stock and Incentive Compensation Plan and the MetLife, Inc. 2015 Stock and Incentive Compensation Plan (the “2015 Stock Plan”) were outstanding at March 31, 2016. All awards granted in 2015 or later were granted under the 2015 Stock Plan. There were no outstanding awards to MetLife, Inc. directors, for their service as directors, as of March 31, 2016.
For Performance Share and Performance Unit awards outstanding as of March 31, 2016, any vested Performance Shares and Performance Units will be multiplied by a performance factor of 0% to 175%. Assuming that MetLife, Inc. has met threshold performance goals related to its adjusted income or total shareholder return, the MetLife, Inc. Compensation Committee will determine the performance factor in its discretion. In doing so, the Compensation Committee may consider MetLife, Inc.’s total shareholder return relative to the performance of its competitors and MetLife, Inc.’s operating return on equity relative to its business plan. The estimated fair value of Performance Shares and Performance Units will be remeasured each quarter until they become payable.
Payout of 2013 – 2015 Performance Shares and Performance Units
Final Performance Shares are paid in shares of MetLife, Inc. common stock. Final Performance Units are payable in cash equal to the closing price of MetLife, Inc. common stock on a date following the last day of the three-year performance period. The performance factor for the January 1, 2013 – December 31, 2015 performance period was 86.2%. This factor has been applied to the 1,592,650 Performance Shares and 234,787 Performance Units associated with that performance period that vested on December 31, 2015. As a result, in the first quarter of 2016, MetLife, Inc. issued 1,372,864 shares of its common stock (less withholding for taxes and other items, as applicable), excluding shares that payees choose to defer, and MetLife, Inc. or its affiliates paid the cash value of 202,386 units (less withholding for taxes and other items, as applicable).
Accumulated Other Comprehensive Income (Loss)
Information regarding changes in the balances of each component of AOCI attributable to MetLife, Inc., was as follows:
 
Three Months 
 Ended 
 March 31, 2016
 
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
 
Unrealized
Gains (Losses)
on Derivatives
 
Foreign
Currency
Translation
Adjustments
 
Defined
Benefit
Plans
Adjustment
 
Total
 
(In millions)
Balance, beginning of period
$
10,315

 
$
1,458

 
$
(4,950
)
 
$
(2,052
)
 
$
4,771

OCI before reclassifications
7,670

 
696

 
551

 

 
8,917

Deferred income tax benefit (expense)
(2,549
)
 
(199
)
 
117

 

 
(2,631
)
AOCI before reclassifications, net of income tax
15,436

 
1,955

 
(4,282
)
 
(2,052
)
 
11,057

Amounts reclassified from AOCI
17

 
(323
)
 

 
48

 
(258
)
Deferred income tax benefit (expense)
(7
)
 
93

 

 
(20
)
 
66

Amounts reclassified from AOCI, net of income tax
10

 
(230
)
 

 
28

 
(192
)
Balance, end of period
$
15,446

 
$
1,725

 
$
(4,282
)
 
$
(2,024
)
 
$
10,865

 
Three Months 
 Ended 
 March 31, 2015
 
Unrealized
Investment Gains
(Losses), Net of
Related Offsets (1)
 
Unrealized
Gains (Losses)
on Derivatives
 
Foreign
Currency
Translation
Adjustments
 
Defined
Benefit
Plans
Adjustment
 
Total
 
(In millions)
Balance, beginning of period
$
15,159

 
$
1,076

 
$
(3,303
)
 
$
(2,283
)
 
$
10,649

OCI before reclassifications
1,626

 
187

 
(670
)
 

 
1,143

Deferred income tax benefit (expense)
(501
)
 
(66
)
 
(13
)
 

 
(580
)
AOCI before reclassifications, net of income tax
16,284

 
1,197

 
(3,986
)
 
(2,283
)
 
11,212

Amounts reclassified from AOCI
(113
)
 
554

 

 
57

 
498

Deferred income tax benefit (expense)
35

 
(196
)
 

 
(20
)
 
(181
)
Amounts reclassified from AOCI, net of income tax
(78
)
 
358

 

 
37

 
317

Balance, end of period
$
16,206

 
$
1,555

 
$
(3,986
)
 
$
(2,246
)
 
$
11,529

__________________
(1)
See Note 6 for information on offsets to investments related to future policy benefits, DAC, VOBA and DSI, and the policyholder dividend obligation.
Information regarding amounts reclassified out of each component of AOCI was as follows:
AOCI Components
Amounts Reclassified from AOCI
 
Consolidated Statement of Operations and
Comprehensive Income (Loss) Locations
 
 
Three Months 
 Ended 
 March 31,
 
 
 
 
2016
 
2015
 
 
 
(In millions)
 
 
Net unrealized investment gains (losses):
 
 
 
 
 
 
Net unrealized investment gains (losses)
 
$
(33
)
 
$
139

 
Net investment gains (losses)
Net unrealized investment gains (losses)
 
3

 
40

 
Net investment income
Net unrealized investment gains (losses)
 
13

 
(66
)
 
Net derivative gains (losses)
Net unrealized investment gains (losses), before income tax
 
(17
)
 
113

 
 
Income tax (expense) benefit
 
7

 
(35
)
 
 
Net unrealized investment gains (losses), net of income tax
 
$
(10
)
 
$
78

 
 
Unrealized gains (losses) on derivatives - cash flow hedges:
 
 
 
 
 
 
Interest rate swaps
 
$
10

 
$
5

 
Net derivative gains (losses)
Interest rate swaps
 
3

 
3

 
Net investment income
Interest rate forwards
 
2

 
3

 
Net derivative gains (losses)
Interest rate forwards
 
1

 
1

 
Net investment income
Interest rate forwards
 

 
1

 
Other expenses
Foreign currency swaps
 
306

 
(567
)
 
Net derivative gains (losses)
Foreign currency swaps
 
1

 

 
Other expenses
Gains (losses) on cash flow hedges, before income tax
 
323

 
(554
)
 
 
Income tax (expense) benefit
 
(93
)
 
196

 
 
Gains (losses) on cash flow hedges, net of income tax
 
$
230

 
$
(358
)
 
 
 
 
 
 
 
 
 
Defined benefit plans adjustment: (1)
 
 
 
 
 
 
Amortization of net actuarial gains (losses)
 
$
(51
)
 
$
(58
)
 
 
Amortization of prior service (costs) credit
 
3

 
1

 
 
Amortization of defined benefit plan items, before
 income tax
 
(48
)
 
(57
)
 
 
Income tax (expense) benefit
 
20

 
20

 
 
Amortization of defined benefit plan items, net of income tax
 
$
(28
)
 
$
(37
)
 
 
Total reclassifications, net of income tax
 
$
192

 
$
(317
)
 
 
__________________
(1)
These AOCI components are included in the computation of net periodic benefit costs. See Note 11.